NCT04158102View on ClinicalTrials.gov

Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 7, 2019

Primary Completion Date

December 17, 2019

Study Completion Date

December 26, 2019

Conditions
Healthy Subjects
Interventions
DRUG

Bupivacaine liposome injectable suspension

Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL

Trial Locations (1)

999077

HUK Phase 1 clinical trials center, Hong Kong

All Listed Sponsors
lead

Nuance Pharma (shanghai) Co., Ltd

INDUSTRY

NCT04158102 - Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter